Nestle Health Science is to take full ownership of the food allergy company Aimmune Therapeutics Inc in an all-cash transaction that values the company at $2.6 billion. Nestle already owns 25.6% of Aimmune and will acquire the remaining equity for $34.50 per share, representing a 174% premium to the company’s closing share price on Nasdaq on 28 August.
